S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway

Collegium Pharmaceutical (COLL) Competitors

$37.13
+0.42 (+1.14%)
(As of 03/1/2024 ET)

COLL vs. AVDL, ARCT, TNGX, RNA, ANIP, GERN, VERV, CNTA, BLTE, and MGNX

Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Avadel Pharmaceuticals (AVDL), Arcturus Therapeutics (ARCT), Tango Therapeutics (TNGX), Avidity Biosciences (RNA), ANI Pharmaceuticals (ANIP), Geron (GERN), Verve Therapeutics (VERV), Centessa Pharmaceuticals (CNTA), Belite Bio (BLTE), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical preparations" industry.

Collegium Pharmaceutical vs.

Avadel Pharmaceuticals (NASDAQ:AVDL) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Collegium Pharmaceutical had 3 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 15 mentions for Collegium Pharmaceutical and 12 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 0.48 beat Collegium Pharmaceutical's score of 0.45 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avadel Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Collegium Pharmaceutical
3 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Collegium Pharmaceutical received 50 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 65.09% of users gave Collegium Pharmaceutical an outperform vote while only 64.59% of users gave Avadel Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Avadel PharmaceuticalsOutperform Votes
321
64.59%
Underperform Votes
176
35.41%
Collegium PharmaceuticalOutperform Votes
371
65.09%
Underperform Votes
199
34.91%

Collegium Pharmaceutical has a net margin of 8.50% compared to Collegium Pharmaceutical's net margin of 0.00%. Avadel Pharmaceuticals' return on equity of 107.39% beat Collegium Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Avadel PharmaceuticalsN/A -306.46% -87.70%
Collegium Pharmaceutical 8.50%107.39%17.07%

Collegium Pharmaceutical has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avadel PharmaceuticalsN/AN/A-$137.46M-$2.01-6.83
Collegium Pharmaceutical$566.77M2.09$48.15M$1.1831.47

Avadel Pharmaceuticals has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Avadel Pharmaceuticals presently has a consensus target price of $19.86, indicating a potential upside of 44.73%. Collegium Pharmaceutical has a consensus target price of $39.00, indicating a potential upside of 5.04%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, research analysts plainly believe Avadel Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avadel Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Collegium Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

71.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 4.0% of Avadel Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats Avadel Pharmaceuticals on 11 of the 17 factors compared between the two stocks.


Get Collegium Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COLL vs. The Competition

MetricCollegium PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.19B$6.75B$5.11B$7.64B
Dividend YieldN/A2.83%2.82%3.87%
P/E Ratio31.478.49176.0014.93
Price / Sales2.09235.673,056.3377.06
Price / Cash3.4519.33100.6555.48
Price / Book6.084.654.534.53
Net Income$48.15M$155.01M$115.01M$211.55M
7 Day Performance2.15%7.79%5.72%3.36%
1 Month Performance13.06%15.91%12.82%6.70%
1 Year Performance37.82%8.07%12.94%7.44%

Collegium Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVDL
Avadel Pharmaceuticals
2.2908 of 5 stars
$13.31
+2.5%
$19.86
+49.2%
+45.2%$1.20BN/A-6.1641Earnings Report
Upcoming Earnings
Options Volume
News Coverage
Positive News
ARCT
Arcturus Therapeutics
2.7835 of 5 stars
$42.99
+5.0%
$56.43
+31.3%
+149.7%$1.15B$206M11.91170Upcoming Earnings
TNGX
Tango Therapeutics
2.3668 of 5 stars
$11.80
+3.8%
$16.67
+41.2%
+115.8%$1.20B$24.86M-10.63110Positive News
RNA
Avidity Biosciences
1.0493 of 5 stars
$15.31
+5.5%
$31.60
+106.4%
-15.3%$1.13B$9.22M-5.12186Analyst Report
Analyst Revision
News Coverage
ANIP
ANI Pharmaceuticals
4.9269 of 5 stars
$59.94
-0.5%
$72.33
+20.7%
+51.3%$1.23B$316.39M115.27600Analyst Report
Options Volume
News Coverage
GERN
Geron
3.2509 of 5 stars
$2.07
flat
$4.67
+126.0%
-19.3%$1.12B$600,000.00-6.07107Earnings Report
Analyst Report
Short Interest ↑
Analyst Revision
News Coverage
VERV
Verve Therapeutics
1.571 of 5 stars
$17.54
+21.5%
$34.25
+95.3%
-19.2%$1.12B$1.94M-5.66204Earnings Report
Analyst Report
Analyst Revision
News Coverage
High Trading Volume
CNTA
Centessa Pharmaceuticals
0.5359 of 5 stars
$11.36
+0.6%
$9.43
-17.0%
+201.1%$1.11BN/A-6.9375Short Interest ↑
Positive News
BLTE
Belite Bio
1.0391 of 5 stars
$46.15
-1.3%
$44.83
-2.9%
+44.4%$1.27BN/A0.0016Short Interest ↓
Positive News
MGNX
MacroGenics
3.4178 of 5 stars
$17.26
+2.7%
$14.00
-18.9%
+208.4%$1.07B$151.94M21.58357Upcoming Earnings
Analyst Report
Insider Selling
Short Interest ↓
News Coverage

Related Companies and Tools

This page (NASDAQ:COLL) was last updated on 3/3/2024 by MarketBeat.com Staff